John Hinkle, MD
Ophthalmology · South Burlington, VTNPI 1821484981
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $2,646 of the $3,553 with a category attached, or 74.5%. Apellis Pharmaceuticals, Inc. accounts for 82.5% of it on its own, with 6 other manufacturers making up the rest. 2025 is the largest year on record at $2,930, 7.4 times the $398 reported in 2019. Among ophthalmology clinicians in VT with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 10 payments — averaging $355.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Apellis Pharmaceuticals, Inc.$3K
- AbbVie$187
- Regeneron Healthcare Solutions, Inc.$149
- Alimera Sciences, Inc.$125
- Mallinckrodt Enterprises LLC$124
- Genentech USA, Inc.$22
- plus $16 from 1 others
What the payments were for
- Consulting fees$2,64674%
- Travel & lodging$2848%
- Food & beverage$62318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Apellis Pharmaceuticals, Inc. | 2 | $2,930 |
| AbbVie | 3 | $187 |
| Regeneron Healthcare Solutions, Inc. | 1 | $149 |
| Alimera Sciences, Inc. | 1 | $125 |
| Mallinckrodt Enterprises LLC | 1 | $124 |
| Genentech USA, Inc. | 1 | $22 |
| Bausch & Lomb Americas Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,553 in reported general payments places this provider in the 90th percentile of 35 ophthalmology providers in Vermont.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Prednisolone Acetate | 168 | $6,120 |
| Bromfenac Sodium | 22 | $5,203 |
| Ketorolac Tromethamine | 57 | $1,778 |
| Ofloxacin | 57 | $617 |
| Atropine Sulfate | 15 | $448 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in South Burlington
- Shaunak BakshiSouth Burlington$4K
- Jonathan ManhardSouth Burlington$2K
- Michelle YoungSouth Burlington$41
- Katherine LaneSouth Burlington$14
- Juli LarsonSouth Burlington$0
- Gregory McCormickSouth Burlington$0
- David WeissgoldSouth Burlington$0
- Christopher ConnorWindsor$187K
- Stephen PhippsSt Johnsbury$1K
- Jillian KaplitaMiddlebury$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.